Aldeyra Therapeutics

ALDX

Market cap $328M

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. Brady's conversation with Andreas Argyrides, Managing Director, Senior Biotech.

The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Aldeyra's Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a procedural PDUFA extension. Reproxalap's Chamber Phase 3 trial met symptom endpoints with rapid, durable relief. However, the main risk is that the field trial missed the primary symptom endpoint while showing supportive signals.

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Fol.

Aldeyra Therapeutics, Inc. ( ALDX ) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye November 13, 2025 8:00 AM EST Company Participants Laura Nichols - Operations Manager Todd Brady - CEO, President & Director Adam Lazorchak Conference Call Participants Thomas Shrader - BTIG, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Clara Dong Yale Jen Presentation Operator Hello, and welcome, everyone, to the Aldeyra Therapeutics 2025 Research and Development Update Webcast. My name is Becky, and I'll be your operator today.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided updated manufacturing information on reproxalap. Based on new preclinical results in models of Pa.